Corticotropin-releasing factor receptor antagonists

被引:12
作者
Gilligan, Paul J. [1 ]
机构
[1] Bristol Myers Squibb Co, Hopewell, NJ 08543 USA
关键词
antagonist; anxiety; corticotropin-releasing factor; depression; stress;
D O I
10.1517/13543776.16.7.913
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Corticotropin-releasing factor (CRF) coordinates the neural, endocrine and immune responses of the body to stress. Therefore, CRF receptors are important targets for the design of drugs for depression, anxiety and stress-related disorders. Several laboratories have published extensive preclinical and limited clinical research into the role of CRF in human disease. This review covers developments in the patent literature during 2002 - 2006 and outlines the prospects for CRF-based therapy for mental illness.
引用
收藏
页码:913 / 924
页数:12
相关论文
共 73 条
[1]  
[Anonymous], [No title captured]
[2]   Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines [J].
Arvanitis, AG ;
Gilligan, PJ ;
Chorvat, RJ ;
Cheeseman, RS ;
Christos, TE ;
Bakthavatchalam, R ;
Beck, JP ;
Cocuzza, AJ ;
Hobbs, FW ;
Wilde, RG ;
Arnold, C ;
Chidester, D ;
Curry, M ;
He, LQ ;
Hollis, A ;
Klaczkiewicz, J ;
Krenitsky, PJ ;
Rescinito, JP ;
Scholfield, E ;
Culp, S ;
De Souza, EB ;
Fitzgerald, L ;
Grigoriadis, D ;
Tam, SW ;
Wong, YN ;
Huang, SM ;
Shen, HL .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (05) :805-818
[3]   CRF and CRF receptors: Role in stress responsivity and other behaviors [J].
Bale, TL ;
Vale, WW .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 :525-557
[4]  
BRISTOL MYERS SQUIBB, 2005, Patent No. 6960583
[5]  
BRISTOL MYERS SQUIBB, 2003, Patent No. 2003005969
[6]  
BRISTOL MYERS SQUIBB, 2002, Patent No. 2002024200
[7]  
BRISTOL MYERS SQUIBB, 2003, Patent No. 2003022820
[8]  
BRISTOL MYERS SQUIBB, 2005, Patent No. 6958341
[9]  
BRISTOL MYERS SQUIBB, 2002, Patent No. 2002092090
[10]  
BRISTOL MYERS SQUIBB, 2003, Patent No. 2003006015